The latest funding rounds, like ArriVent’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New funding rounds, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Industry Trends
See who's moving and how much in your market
No credit card required Weekly funding digest
Arrivent Biopharma Announces $250 Million at-the-market Offering
PUBLIC · AVBPMay 11, 2026•about 1 month ago
Amount Raised
$250 Million
Round Type
at-the-market offering
Newtown SquareBiotechnology
Investors
Jefferies Llc
Description
On May 11, 2026, Arrivent Biopharma, Inc. filed a prospectus supplement with the SEC regarding its existing at-the-market offering program. The company may offer and sell shares of common stock with an aggregate offering price of up to $250 million through Jefferies LLC as the sales agent. This initiative is part of their ongoing capital-raising efforts to support the company's development objectives.
Company Information
Company
ArriVent
Location
Newtown Square, Pennsylvania, United States
About
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
Newtown SquareBiotechnology